新型抗雄激素靶向研究分析(TITAN)研究:阿帕他胺联合雄激素剥夺治疗实现超低前列腺特异性抗原下降
TITAN研究事后分析评估转移性去势敏感性前列腺癌(mCSPC)患者达到PSA≤0.2 ng/mL与临床结局的关联。患者随机接受阿帕他胺240 mg/日(n=525)或安慰剂(n=527)联合ADT。阿帕他胺组3个月内达到超低PSA者更多,且超低PSA与更长的rPFS、OS、TTCRPC和TTPP相关。
要点
- 3个月时阿帕他胺组38%和23%达到UL1和UL2,安慰剂组为15%和5%。
- 阿帕他胺组UL2 vs PSA>0.2 ng/mL的rPFS HR 0.28,OS HR 0.24。
- 阿帕他胺组UL2 vs PSA>0.2 ng/mL的TTCRPC HR 0.2,TTPP HR 0.11(名义P均<0.001)。
核心结论
- 在TITAN研究的事后分析中,PSA下降最深的患者获益最大。
- 这些结果扩展了阿帕他胺在整体TITAN人群中疗效的发现,强调PSA动力学作为治疗疗效标志物的临床价值。
研究设计与样本
- TITAN研究(ClinicalTrials.gov标识NCT02489318)的事后分析,纳入mCSPC患者。
- 患者随机接受阿帕他胺240 mg/日(n=525)或安慰剂(n=527)联合雄激素剥夺治疗。
- 评估达到PSA 0.2->0.02 ng/mL(UL1)和≤0.02 ng/mL(UL2)vs >0.2 ng/mL与rPFS、OS、TTCRPC和TTPP的关联。
- 采用里程碑分析和Kaplan-Meier方法。
主要发现
- 3个月时,阿帕他胺组38%和23%达到UL1和UL2,安慰剂组为15%和5%。
- 在阿帕他胺治疗患者中,3个月里程碑时UL2 vs PSA>0.2 ng/mL与显著更长的rPFS(HR 0.28,95%CI 0.14-0.54)、OS(HR 0.24,95%CI 0.13-0.43)、TTCRPC(HR 0.2,95%CI 0.11-0.38)和TTPP(HR 0.11,95%CI 0.04-0.27;名义P值均<0.001)相关。
- UL1也观察到这种关联,但较不显著。
- 6个月时观察到类似发现。
- 在阿帕他胺治疗患者中,3个月内早期下降至UL2 vs 任何时候PSA>0.2 ng/mL与改善的生存相关(HR 0.12,95%CI 0.06-0.22;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between achievement of prostate-specific antigen (PSA) levels ≤0.2 ng/mL (henceforth 'ultralow') and clinical outcomes in patients in the 'Targeted Investigational Treatment Analysis of Novel Anti-androgen' (TITAN) study (ClinicalTrials.gov Identifier NCT02489318) with metastatic castration-sensitive prostate cancer (mCSPC). PATIENTS AND METHODS: Patients in the TITAN study with mCSPC were randomised to 240 mg/day apalutamide (n = 525) or placebo (n = 527) plus androgen-deprivation therapy. This post hoc analysis assessed the achievement of a PSA level of 0.2->0.02 ng/mL ('ultralow one' [UL1]) and ≤0.02 ng/mL ('ultralow two' [UL2]) vs >0.2 ng/mL with apalutamide treatment and its association with radiographic progression-free survival (rPFS), overall survival (OS), time to castration-resistant PC (TTCRPC), and time to PSA progression (TTPP). The landmark analysis and Kaplan-Meier methods were used. RESULTS: By 3 months, more patients achieved UL1 and UL2 with apalutamide (38% and 23%) vs placebo (15% and 5%). In the apalutamide-treated patients, UL2 vs PSA >0.2 ng/mL at landmark 3 months was associated with significantly longer rPFS (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.14-0.54), OS (HR 0.24, 95% CI 0.13-0.43), TTCRPC (HR 0.2, 95% CI 0.11-0.38), and TTPP (HR 0.11, 95% CI 0.04-0.27; nominal P values all <0.001); this association was also observed but less pronounced for UL1. Similar findings were observed at 6 months. Early onset of decline to UL2 by 3 months was associated with improved survival vs PSA >0.2 ng/mL anytime (HR 0.12, 95% CI 0.06-0.22; P < 0.001) in apalutamide-treated patients. CONCLUSIONS: In this post hoc analysis of TITAN, patients with the deepest PSA decline derived the greatest benefit. These results extend our findings of apalutamide efficacy in the overall TITAN population, underscoring the clinical value of PSA kinetics as a marker for treatment efficacy. PATIENT SUMMARY: Patients with metastatic prostate cancer that is sensitive to ongoing hormonal treatment benefited significantly from the addition of apalutamide compared with placebo. Those who achieved rapid and deep PSA reduction had the greatest survival benefit.
引用
- Merseburger AS, Agarwal N, Bjartell A, et al. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU Int. 2024. PMID: 38940282. doi:10.1111/bju.16449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。